Eshelman Ventures
VC Fund
Wilmington, United States
Eshelman Ventures is a VC fund in Wilmington focused on Biotechnology and Therapeutics. Eshelman Ventures, based in New Castle, provides investment to private healthcare companies.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 47%
Last updated:
For AI agents: llms.txt
Industries Eshelman Ventures invests in
Stages Eshelman Ventures invests in
Countries Eshelman Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Fred Eshelman
|
|||
Investment Focus
Industry
- Biotechnology 11 (58%)
- Therapeutics 7 (37%)
- Medical 6 (32%)
- Health Care 6 (32%)
- Pharmaceutical 4 (21%)
Stage
- Series B 4 (21%)
- Venture - Series Unknown 3 (16%)
- Series A 2 (11%)
- Series C 2 (11%)
- Funding Round 2 (11%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Fred Eshelman
Founder
|
Founder | Total investments: 8 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers. Founded by Patrick Roberts, Jay Strum, John Bisi, and Fred Eshelman in 2020 and is headquartered in Durham, North Carolina. | $11.2M / Series B / Aug 22, 2025 | ||
| Jupiter BioVentures is a creation engine company that focuses on de-risking early-stage projects. | $70M / Venture - Series Unknown / Nov 19, 2024 | ||
| Aravive is a clinical-stage biotechnology company. It focuses on developing therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. | $41.5M / Post-IPO Equity / Oct 25, 2022 | ||
| Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme(GBM), which is the most severe and deadly form of brain cancer.The company was founded in 2015 by Barry Kappel and is based in Scarsdale, New York, United States. | $41M / Series B / May 31, 2022 | ||
| Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers. Founded by Patrick Roberts, Jay Strum, John Bisi, and Fred Eshelman in 2020 and is headquartered in Durham, North Carolina. | $30M / Series B / Mar 31, 2022 | ||
| Aravive is a clinical-stage biotechnology company. It focuses on developing therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. | $10M / Post-IPO Equity / Jan 03, 2022 | ||
| Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers. Founded by Patrick Roberts, Jay Strum, John Bisi, and Fred Eshelman in 2020 and is headquartered in Durham, North Carolina. | $6M / Venture - Series Unknown / Aug 06, 2020 | ||
| Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed toimprove the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration. | $22.4M / Post-IPO Equity / Dec 26, 2019 | ||
| Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers. Its mission is to expand the reach of targeted therapeutics by developing products for underserved populations. The company utilizes its deep expertise in structure-based drug discovery, translational research, and patient-drivenprecision medicine. Its programs include candidates in preclinical development for cancers that are driven by specific oncogenic alterations in either the BRAF kinase gene or in the FGFR2 and FGFR3 kinase genes. | $74.5M / Series B / Dec 19, 2019 | ||
| ArunA Biomedical is a research company that specializes in the fields of stem cells, neural stem cells, drug toxicity assay. It is harnessing the natural abilities of neural exosomes to cross the blood-brain barrier and enhance the body’s anti-inflammatory, self-repair, and protective mechanisms. | $13M / Jul 24, 2019 | ||
| See all 19 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Eshelman Ventures invest in?
Eshelman Ventures invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Series B and Venture - Series Unknown stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Eshelman Ventures?
Public channels for Eshelman Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Eshelman Ventures?
The team at Eshelman Ventures includes Fred Eshelman (Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
